CEFAZOLIN FOR INJECTION POWDER FOR SOLUTION

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

CEFAZOLIN (CEFAZOLIN SODIUM)

から入手可能:

TEVA CANADA LIMITED

ATCコード:

J01DB04

INN（国際名）:

CEFAZOLIN

投薬量:

10G

医薬品形態:

POWDER FOR SOLUTION

構図:

CEFAZOLIN (CEFAZOLIN SODIUM) 10G

投与経路:

INTRAVENOUS

パッケージ内のユニット:

1

処方タイプ:

Prescription

治療領域:

FIRST GENERATION CEPHALOSPORINS

製品概要:

Active ingredient group (AIG) number: 0109442003; AHFS:

認証ステータス:

APPROVED

承認日:

2013-04-12

製品の特徴

_Pr_
_CEFAZOLIN FOR INJECTION Product Monograph Page 1 of 21 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
CEFAZOLIN FOR INJECTION
POWDER FOR SOLUTION, 500 MG, 1.0 G AND 10.0 G, CEFAZOLIN (AS CEFAZOLIN
SODIUM) PER VIAL
Intravenous, Intramuscular
USP
Antibiotic
Teva Canada Limited
Date of Initial Authorization:
30 Novopharm Court
January 19, 1995
Toronto, Ontario
M1B 2K9
Date of Revision:
Canada
MAR 15, 2024
www.tevacanada.com
Submission Control Number: 265641
_Pr_
_CEFAZOLIN FOR INJECTION (Cefazolin Sodium) Product Monograph Page 2
of 21 _
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS
11/2020
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.....................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
1 INDICATIONS
..........................................................................................................................
3
2 CONTRAINDICATIONS
.........................................................................................................
4
4
DOSAGE AND ADMINISTRATION
......................................................................................
4
4.2 Recommended Dose and Dosage Adjustment
......................................................................
4
4.3 Reconstitution
.......................................................................................................................
6
4.4 Administration
......................................................................................................................
8
5 OVERDOSAGE
.........................................................................................................................
8
6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKA